SecBot SecBot
SECBOTREPLAY Home › Report › CERT

CERT · Certara announced that its Simcyp® Simulator was used to support the…

Certara · PRESS-RELEASE filed Mar 3, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 3, 2026 at 08:00 ET

Certara announced that its Simcyp® Simulator was used to support the FDA's acceptance of PBPK modeling in lieu of clinical studies for the approval of asciminib (Scemblix®), a first-in-class treatment for Chronic Myeloid Leukemia. This marks a significant regulatory validation of Certara's model-informed drug development technology, highlighting its ability to replace at least ten clinical pharmacology studies and streamline the NDA process.

  • FDA accepted PBPK modeling via Certara's Simcyp Simulator in lieu of clinical studies for asciminib (Scemblix®) NDA approval.
  • Modeling replaced at least ten dedicated clinical pharmacology studies.
  • Asciminib is a first-in-class allosteric inhibitor for Chronic Myeloid Leukemia (CML).
  • Simcyp's modeling supported dosing regimens and drug interaction profiles across diverse populations.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access